Updated

An investigation found that pharmaceutical companies have increasingly used add-on patents to extend exclusivity on drugs, pushing effective patent protection periods from about two years to over six. Critics say the practice, sometimes called 'patent thickets,' delays generic competition and keeps drug prices artificially high. The findings add to ongoing debates in the US over drug pricing reform and pharmaceutical industry practices.